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1. Introduction 
Oral reactions to medications are common and affect patients’ quality of life. Almost all 
classes of drugs, particularly those used continuously, such as antidepressants, anti-
hypertensives, anxiolytics, hypnotics, diuretics, antipsychotics among others, including 
vitamins, minerals and phyto-pharmaceuticals, may cause oral alterations. If not suitably 
treated, these may aggravate the patient’s general state of health and affect his/her oral 
health (Lamy, 1984; Smith & Burtner, 1994; Rees, 1998; Ciancio, 2004; American Dental 
Association [ADA], 2005; Scelza et al., 2010). 
Prescribed and over-the-counter medications are frequently used in large quantities and by 
many adults, particularly by those over the age of 65 years. The abusive use of drugs, mainly 
by elderly patients, may generate oral side effects (Lamy, 1984; Ciancio, 2004; ADA, 2005). 
The number of prescriptions in the USA is mainly due to the therapeutic advances in the 
treatment of various medical conditions and the increase in the geriatric population. Josephe 
et al. (2003) observed that 21% of the 1,800 patient dental records reviewed showed 
antidepressant use. It is suspected that the prevalence of oral lesions increases in direct 
relation to the increase in the use of necessary drugs, mainly to control chronic diseases. 
Over 200 drugs are involved in adverse reactions and side effects on oral tissues. Smith & 
Burtner (1994) founded as oral side-effects of the most frequently prescribed drugs: dry 
mouth (80.5%), dysgeusia (47.5%) and stomatitis (33.9%). 
Xerostomia, a subjective dry mouth sensation, is a side effect of around 400 medications. 
Moreover, it is one of the major problems in the USA at present, affecting millions of 
persons. Diminishment or absence of saliva may affect the emotional well being, cause 
significant morbidity and a reduction in the patient’s quality of life (Ciancio, 2004; Fox et al., 
1985; Sreebny & Schwartz, 1986; Sreebny & Valdini, 1987; Butt, 1991; Guggenheimer & 
Moore, 2003). Thus, a dental and medical record of the patient is necessary, with regular 
updating of the prescribed medications, because of the potential side effects of drugs and 
interactions among them. It is also important for dentists to know about the problems related 
to medication and the impact of this on diagnosis and the treatment plan (Keene et al., 2003). 
2. Antidepressant 
Psychotropic drugs are those that act on the central nervous system (SNC) producing 
alterations in behaviour, mood and cognition, and that may lead to dependence. 
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The use of psychotropic has increased over the last few decades in several countries. This 
growth has been attributed to the increased frequency of psychiatric disturbance diagnoses 
in the population, the introduction of new psycho pharmaceuticals on the pharmaceutical 
market and the new therapeutic indications of existent psychotropics (Rodrigues, 2006). 
Patients that take psychotropic medications for long periods may experience behaviours 
that have a negative impact on oral health. These medications may cause lethargy, fatigue 
and lack of motor control and memory that may impair the individual’s ability to practice a 
good oral hygiene technique (McClain et al., 1991). Furthermore, a large number of 
medications used for the treatment of psychiatric diseases, have the side effects of dry 
mouth, diminished salivary flow speed and/or alteration in saliva composition (Sreebny 
& Schwartz, 1997; Loesche et al., 1995; Bardow et al., 2001). Zaclikevis et al. (2009) 
observed that psychotropic drugs caused hyposalivation in rats and acinar hypertrophy in 
their parotid glands. De Almeida et al. (2009) observed that psychotropic users presented 
a significant decrease in the stimulated salivary flow rate compared with the control 
group. 
Antidepressants are medications prescribed to patients of all ages (Von Knorring & Wahlin, 
1986; Meskin & Berg, 2000), for the treatment of a variety of psychiatric diseases (depression, 
affective disease, insomnia, anxiety, the panic syndrome and bipolar disorder). In addition, 
they are also prescribed for the treatment of some medical conditions, such as rheumatoid 
arthritis, dietary disorders, fibromyalgia, migraine, trigeminal neuralgia, pre-menstrual 
tension (Keene et al., 2003). 
Antidepressant drugs were discovered in the early 1950s, with the development of the 
monoamine-oxidase inhibitors (MAOIs). MAO is the enzyme responsible for the 
degradation of various neurotransmitters, including adrenalin, serotonin, noradrenalin and 
dopamine. It is believed that MAO inhibition alleviates depression, allowing serotonin and 
noradrenalin to accumulate at the synaptic junction, in the storage locations, in the SNC and 
the independent sympathetic system (Perry et al., 1997). The following are examples of this 
class of antidepressants: tranylcypromine, moclobemide and selegiline. 
In addition to the MAOIs, there are tricyclic antidepressants (TCAs) that are relatively non 
selective, acting not only on the serotonergic and noradrenergic systems, but also on the 
muscarinic, histaminergic and α- adrenergic systems (Messer et al., 1997). Their efficiency 
appears to be related to the increase in serotonin and noradrenalin, and to a lesser extent, of 
dopamine, at the synaptic gap (Stahl, 1992).  Amitriptyline, imipramine, clomipramine and 
nortriptyline are some examples of tricyclic antidepressants. 
The selective serotonin recapture inhibitors (SSRIs), such as:  citalopram, fluoxetine, 
fluvoxamine, paroxetine and sertraline, represent another class of antidepressants that 
increase the availability of serotonin at the post-synaptic terminals by means of blocking 
recapture at the pre-synaptic terminal (Coccaro & Siever, 1985; Friedlander et al., 2002; 
Preskorn et al., 2004). The SSRIs appear to have fewer side effects than the TCAs, which 
present significant anticolinergic and cardiovascular effects (Keene et al., 2003). 
The serotonin-noradrenalin recapture inhibitors are a new class of antidepressants, of which 
the venlafaxine, mirtazapine, trazodone and nefazodone form part (Feighner, 1999). 
Venlafaxine, especially, is a potent pre-synaptic inhibitor of serotonin and noradrenalin 
recapture, and a moderate inhibitor of dopamine recapture (Feighner, 1999; Barman Balfour 
& Jarvis, 2000; Wellington K, Perry, 2001). 
Bupropion, an atypical antidepressant, exercises its effect by preventing the reuptake of 
noradrenalin and dopamine at the synaptic gap, thus facilitating neural transmission 
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(Goodnick PJ, Dominguez, 1998). The antidepressant effect of lithium, a mood stabilizing 
agent used to treat the depressive phase of bipolar disorder, may derive from its ability to 
increase the serotonin levels in the SNC (Schou, 1999). 
The majority of antidepressant medications prescribed is associated with a number of 
significant oral reactions (Friedlander & Mahler, 2001). These complications, including 
xerostomia, sialoadenitis, gingivitis, dysgeusia, glossitis, tongue edema and discoloration 
and stomatitis, almost always appear due to dysfunction of the salivary gland induced by 
the medication. But in patients that make use of mirtazapine, the development of stomatitis 
may represent the initial signs of bone marrow suppression induced by the medication, such 
as: agranulocytosis, leukopenia or granulocytosis, a potentially fatal event (Friedlander & 
Norman, 2002). Bertini et al. (2009) reports a case of ulceration of the oral mucosa induced 
by antidepressant medication. 
Rindal et al. (2005) suggest that antidepressant drugs do not generate a raise in the overall 
restoration risk level when compared with a group on non-xerogenic drug. Instead, that 
antidepressant medication raises the quantity of disease for persons already at risk. The 
non-xerogenic group had a superior restoration rate than the no medication group but not 
as high as the antidepressant group rate. 
Studies that assessed the oral health of patients that use antidepressants observed extensive 
tooth losses. This may occur because of various factors: lack of interest in oral hygiene, 
preference for carbohydrates (probably because of the reduction of serotonin in the SNC), 
preference for sweetened foods because of alterations in the sense of taste (dysgeusia), by 
the diminishment of saliva release and by the high lactobacillus counts (Rundegren et al., 
1985; Christensen & Somers, 1996; Anttila et al., 1999). 
Persons with depression are also at high risk of developing periodontal disease, because 
neglected oral hygiene, increased smoking and altered immune response, associated with 
xerostomia facilitate increased colonization by pathologic bacteria in the mouth, leading 
to collapse of the periodontium (Moss et al., 1996; Elter et al., 1999). Patients that receive 
SSRIs or atypical antidepressants may sometimes develop movement disorders that include 
bruxism or tooth-grinding, which may aggravate the patient’s periodontal status (Brow & 
Hong, 1999). These drugs raise the extrapyramidal serotonin levels, thus inhibiting the 
dopaminergic pathways that control the movements (Bostwick & Jaffee, 1999).  
There is consensus among various authors that xerostomia is the main and the commonest 
side effect of antidepressant drugs (Smith & Burtner, 1994; Pajukoski et al., 2001; Ciancio, 
2004; Scully, 2003; Josephe et al., 2003; Thomson et al., 2006; Uher et al., 2009), in addition to 
this, patients that receive antidepressant therapy frequently complain about diminished 
salivation and changes in salivary viscosity (Astor et al., 1999).  
2.1 Role of saliva in oral health 
Saliva is a true mirror of the body that contains a large number of organic and inorganic 
compounds, and can be seen as a very important health indicator. Salivary secretion is 
controlled by the autonomic nervous system through receptors present in the salivary 
gland. Many studies show that medicine and diseases can affect the function of salivary 
glands as regards the quality and quantity of saliva secreted (Greabu et al. 2009; Gregio et 
al., 2006).  
Salivary secretion is complex and occurs subsequent to neurotransmitter stimuli. The 
principal control of secretion is derived from sympathetic and parasymphatetic innervation 
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which regulates the secretory function on the acinar cell level and controls the 
reabsorption process in the striated ducts of salivary glands. Parasympathetic stimulation 
increases the volume of secreted saliva, whereas sympathetic stimulation mainly affects 
protein content and composition. The salivary gland may serve as a model to determine 
the peripheral effects of different antidepressants on the monoaminergic and the 
cholinergic systems. Salivary gland function depends on the integrity of both 
parasympathetic and sympathetic innervation. Normal salivation is an essential demand 
for oral health, due to its important contributions to the oral defense mechanisms. 
Diminished salivary secretion could lead to serious disease and deterioration of the 
mucosa (Von Knorring & Mornstad, 1986;  Hunter& Wilson, 1995) The saliva has several 
important functions in the mouth, including protection of the oral mucosa, chemical 
buffering, digestion, taste, antimicrobial action, and maintaining the integrity of the teeth. 
Due to its glycoprotein contents saliva has a viscous aspect that protects the oral mucosa 
by the formation of a barrier against noxious stimuli, microbial toxins, and minor trauma. 
Its fluid nature facilitates the removal of cell debris and non-adherent bacteria (Edgar, 
1992).  
2.2 Antidepressant and xerostomia 
Xerostomia means a subjective dry mouth sensation and represents a symptom related by 
the patient. It may occur in the presence of systemic diseases or conditions, such as 
displayed on Table 1, or as consequence of use of drugs (Table 2) (Lamy, 1984; Sreebny & 
Schwartz, 1997; Stack & Papas, 2001; Scully, 2003; Guggenheimer & Moore, 2003). Between 
the drugs stands out the antidepressants (Table 3). Patients with xerostomia displayed 
various degrees of discomfort related to the quality of life according to the aetiology of their 
conditions (Cho et al., 2010). Around 1 in 5 people complain of dry mouth, and a rising 
occurrence in the elderly, it is essential to have a complete understanding of this subject 
(Hopcraft & Tan, 2010). 
Of the conditions mentioned above, salivary hypofunction secondary to the use of 
medications is the commonest (Nederfors, 1996; Fox, 1998). They inhibit the cholinergic 
signals in the salivary tissues and thus diminish the excretion of fluids by the glands, and 
interferences in central pathways (serotoninergics and dopaminergics) may also alter 
salivary composition (Atkinson & Baum, 2001). The normal stimulated salivary flow rate is 
between 0.7 to 1 mL/min, whereas hyposalivation is considered when the salivar 
production is under 0.7 mL/min (Tenovuo & Lagerlöf, 1994).  
 Aging has a minimum impact on salivary flow, but the advance of age and the appearance 
of chronic diseases lead to the use of drugs that may diminish the salivary flow by up to 
40% (Sreebny & Schwartz, 1997; Ben-Aryeh et al., 2001). Complaints of xerostomia may 
increase three-fold in elderly patients that receive xerogenic medication (Osterberg et al., 
1984). 
In a study comparing the use of escitalopram and nortriptyline, Uher et al. (2009) observed 
that dry mouth was the most commonly reported adverse effect, and that it was more 
common during treatment with either nortriptyline or escitalopram than in the medication-
free state. The authors also demonstrated a positive correlation with the dose of both 
antidepressants. 
There is evidence that the prevalence of dry mouth is correlated to polymedication (Locker, 
1995; Nederfors et al., 1997). But, Persson et al. (1991) verified that the use of up to 4 
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different xerogenic medications did not result in significantly additional reduction in the 
salivary flow speed in his patients. 
 
Diseases⁄Conditions 
Salivary aplasia 
Dehydration  
Sarcoidosis 
Cystic fibrosis 
Psycogenic  
Sjögren´s syndrome 
Primary biliary cirrhosis 
Infections (HIV, HTLV-1, Hepatitis C) 
Radiation therapy 
Renal dialysis 
Vasculits 
Bone marrow transplantation 
Anxiety 
Depression 
Graft vs host disease 
Diabetes type 1 or 2 
Diabetes insipidus 
Haemorrhage 
Chemotherapy 
Tabagism 
Oral respiration 
Table 1. Systemic diseases or conditions related with xerostomia 
The subjective dry mouth sensation may occur even in the presence of a normal salivary 
flow that is, not necessarily being associated with a diminution in the amount of saliva 
(Fox et al., 1985; Närhi, 1994). According to Mandel & Wotman (1994) the quality of 
salivary secretion (especially the mucin content) is more important than the quantity in 
the dry mouth sensation. The type of saliva (rest or stimulated), procedures and time of 
collection, composition and source (larger or smaller salivary glands) are factors that can 
contribute to the patient’s report of dry mouth and it relationship with hyposalivation 
(Mandel & Wotman, 1994; Von Knorring & Mörnstad, 1981). According to Nagler (2004), 
in up to one third of cases, xerostomia does not reflect a real reduction in salivary flow 
speed. 
As regards dry mouth, it is due to the reduction in saliva secretion or when its composition 
is altered, and it may cause various clinical problems (Table 4) (Nagler, 2004; Ursache et al., 
2006; Tuner et al., 2007). 
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Drugs 
Skeletal muscle relaxants 
Antihypertensive agents 
Anti-Parkison agents 
Antihistamines 
Antipsychotics 
Diuretics 
Antispasmodics - Scopolamine 
Atropine 
Muscarinic receptor antagonists for treatment of overactive bladder 
Barbiturates 
Clonidine 
Lithium carbonate 
Phenylbutazone 
Psychotropics 
Tri-iodothyronine 
Anticonvulsivants 
Antidysrhythimic 
Anti-incontinence agent 
Ophtalmic formulation 
Smoking cessation agent 
Appetite suppressants 
Antimigraine agents 
Antidepressants 
Descongestionants  
Bronchodilators 
Alfa receptor antagonist for treatment of urinary retention 
Benzodiazepines- Lorazepam 
Opioids- morphine 
Hypnotics 
Retinoids 
Cytokines 
Anti-HIV drugs 
H2 antagonists and proton pump inhibitors 
Cytotoxic agents 
Drugs of abuse 
Anxiolytics 
Table 2. Drugs related with xerostomia 
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Antidepressant 
Serotonin agonists 
Noradrenalin re-uptake blockers 
Serotonin re-uptake inhibitors 
Noradrenalin and Serotonin re-uptake blockers 
Atipical antidepressants 
Tricyclic antidepressants 
Heterocyclic antidepressants 
Monoamine oxidase inhibitors 
Venlafaxine 
Buspirone 
Alprazolan 
Table 3. Antidepressant related with xerostomia 
 
Dental caries 
Dry lips (Fig.1) 
Colourless oral mucosa 
Dry mouth (Fig.2) 
Dysgeusia 
Partially no papilla tongue 
Atrophied papilla and deep fissures (Fig.3) 
Dysphagia 
Gingivitis 
Halitosis 
Mastication problems 
Burning sensation in the mouth 
Mucositis 
Candidiasis 
Poorly fitting prostheses 
Sleeping difficulty 
Difficulty with speech 
Traumatic oral lesions 
Halitosis 
Ulceration 
Periodontal disease 
Saliva  composition changes 
Table 4. Oral effects of hipossalivation 
A variety of technique have used to evaluate xerostomia: questionnaire; visual analogue-
scale; clinical inspection if a tongue blade adheres to the buccal mucosa or if a patient can 
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chew and swallow dried food without water; by quantifying the volume of residual saliva 
on mucosal surfaces using filter paper and micro-moisture meter and calculating thickness; 
and mucosal wetness devices (Osailan et al., 2011). Also, sialometry (salivary flow rate 
measurement) is indicated as part of the diagnostic procedures for hyposalivation (Tenovuo 
& Lagerlöf, 1994), and the composition of saliva can be verified by means of biochemical 
salivary exams. 
 
 
Fig. 1. Clinical presentation: A patient in a coma state showing intense dry lip mucosa 
 
 
Fig. 2. Clinical presentation: A patient showing dry mucosae after use of  medications 
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Fig. 3. Clinical presentation: A patient treated with medication showing tongue with 
atrophied papilla and deep fissures 
Antidepressants have anticolinergic or antimuscarinic action, which acts to block the actions 
of the parasympathetic system by inhibiting the effects of acetylcholine on the salivary gland 
receptors. This results in a dry mouth sensation, probably because the sympathetic portion 
of the independent nervous system predominates over the “blocked” parasympathetic 
system (Wynn et al., 2001). According to Schubert & Izutsu (1987), the drugs may affect the 
salivary flow and its composition by interferences in the acinary and duct functions, and by 
means of alterations in the blood flow of the salivary glands. According to Douglas (2002) 
diminishment of the salivary flow is due to the reduction in the blood flow of the gland, 
produced by adrenergic sympathetic vasoconstriction. Therefore, when there is sympathetic 
hyperactivity the mouth presents dry. 
It is important to emphasize that the dry mouth sensation and alteration in salivary 
composition may occur during periods of stress and/or acute anxiety, frequently present in 
depressive disorders, due to predominant stimulation of the sympathetic system, 
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irrespective of the use of anxiolytic and/or antidepressant medication (Guggenheimer & 
Moore, 2003). Isolated depression is related to diminishment of salivary secretion and to 
xerostomia, due an anticolinergic action (Stack & Papas, 2001; Brown, 1970). Therefore, it 
may be difficult to determine whether these side effects and their intensity arise from the 
medical condition that led to the treatment, or from the medication prescribed for it (Smith 
& Burtner, 1994), it probably is as a result of both. 
2.3 Treatment of hyposalivation 
Various treatments are proposed for enhanced salivary secretion, among them, the use of a 
salivary flow stimulating drug pilocarpine chloride which acts by stimulating the 
parasympathetic ANS (Vivino et al., 1999). This drug has been used because it stimulates the 
cholinergic receptors, among them the muscarinicM3 receptor present in the salivary 
glands, resulting in the expulsion of the stored salivary contents (Ferguson, 1993), thus an 
increase in saliva production and release was observed with the use of cholinergic drugs. 
The next table shows the types of hyposalivation treatment according to Turner & Ship 
(2007), treatment strategies include salivary replacement therapies, as well as use of statory, 
masticatory and pharmacological stimulants.  
 
Gustatory and tactile sialogogues 
Acid-tasting substances 
Acidic (sugar-free) sweets 
Acidic or effervescent drinks (lemon juice, citric acid, buttermilk) 
Citric acid crystals 
Cotton-wool gauze soaked in a citric acid and glycerine solution 
Lemon pastilles 
Lemon slices 
Vitamin C tablets 
Miscellaneous substances 
Dried pieces of reed root (calami rhizome) 
Sugar-free chewing gum 
Sugar-free sweets 
Vegetables or fruits 
Anetholetrithione 
Benzapyrone 
Betanechol chloride 
Carbachol 
Cevimeline 
Folia Jaborandi and tinctura Jaborandi 
Neostigmine, neostigmine bromide, pyridostigmine bromide 
Destigmine bromide 
Nicotinamide and nicotine acid 
Pilocarpine hydrochloridey, pilocarpine nitrate 
Potassium iodide 
Trithioparamethoxyphenylpropene 
Table 5. Treatment of hiposalivation 
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3. Conclusion  
Xerostomia is the main oral side effect associated with the various classes of drugs, 
particularly those used continuously. There is, however, not always a positive correlation 
between hyposalivation and xerostomia. This symptom may be the result of both 
diminished salivary secretion and an alteration in saliva composition. Nevertheless, when 
present, xerostomia may affect the patient’s emotional well being, aggravate his/her general 
state of health, as well as affect his/her oral health, as other reactions such as dygeusia, 
candidosis, caries and stomatitis are reported as being the consequence of xerostomia. It is 
important to emphasize the dentists’ role as regards patients that make use of medications, 
mainly for treating chronic diseases. It is their obligation to keep a detailed and updated 
medical history of their patients, in order to be alert to problems related to medication, and 
the impact of this on the diagnosis and treatment plan, as well as to prepare the most 
adequate and effective preventive programs possible. In order to determine whether or not 
the patient presents hyposalivation, the dentist can have a complementary exam, called 
sialometry (salivary flow speed measurement), may be performed.  If there is any doubt 
about the composition of the saliva, there are biochemical tests that can reveal alteration in 
its composition. Communication between the doctor and dentist is extremely important, so 
that together, they re-establish the patient’s general and oral health as far as possible. 
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